Immunogenicity and tolerability of a heterologous booster typhoid conjugate vaccine (TCV) five to six years after primary vaccination in Burkinabe Children: An open-label, non-randomized follow-up of a phase 2 trial cohort
Abstract
Typhoid fever remains a major public health challenge in low- and middle-income countries. In 2018, the World Health Organization recommended a single dose of typhoid conjugate vaccine (TCV) for routine immunization in endemic settings; however, evidence to inform booster dosing remains limited. This study evaluated the immunogenicity and safety of a heterologous booster strategy using a Vi capsular polysaccharide-CRM197 TCV (Vi-CRM) administered 5–6 years after primary vaccination with a Vi capsular polysaccharide tetanus toxoid TCV (Vi-TT). In this open-label, non-randomized follow-up study, children previously enrolled in a Phase 2 randomized trial in Ouagadougou, Burkina Faso, were re-enrolled. Participants who had received TCV at 9–11 or 15–23 months of age received a Vi-CRM booster at 6–7 years of age (Booster-TCV group), while control participants received their first TCV dose at the same age (1st-TCV group). Group assignment reflected allocation in the parent trial; no new randomization was performed. Serum anti-Vi IgG concentrations were measured before vaccination and 28 days afterward. Seroconversion was defined as a ≥ 4-fold increase from baseline. Solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs) were recorded. Among 147 enrolled children, 87 received a booster dose and 60 received a first TCV dose. Baseline anti-Vi IgG geometric mean titers (GMTs) were higher in the Booster-TCV group than in the 1st-TCV group (21.5 [95% CI, 17.2-26.8] vs 5.5 [95% CI, 4.5-6.8] EU/mL). By day 28, GMTs increased to 5140.0 (95% CI, 4302.0-6141.3) and 2084.8 (95% CI, 1724.4-2520.5) EU/mL, respectively, and all participants with evaluable samples seroconverted. Solicited reactions were infrequent and mild, and no SAEs occurred through day 28. These findings demonstrate robust immunogenicity and short-term tolerability of heterologous TCV boosting; however, because no correlate of protection exists for TCVs, the results do not establish sustained or post-booster clinical protection. Trial registration: ClinicalTrials.gov NCT07624175 (registered 2026-06-03); parent trial NCT03614533
// Source
Authors: Jean Sawadogo, Alimatou Héma, Amidou Diarra, Jean Moïse Tanga Kaboré, Denise Hien, Ludovic Kouraogo, Aminata R. Zou, Amidou Z. Ouedraogo, Alfred B. Tiono, Shrimati Datta, Marcela F. Pasetti, Kathleen Maletic Neuzil, Sodiomon Bienvenu Sirima, Alphonse Ouédraogo, Matthew Brent Laurens
Institutions: University of Maryland, Baltimore, University of Maryland School of Medicine